Caplin Point Laboratories Limited Revenue Breakdown – NSE:CAPLIPOINT
NiveshIQ
NSE: CAPLIPOINT · Healthcare
Caplin Point Laboratories Ltd.
₹2,613.20▲ ₹24.90 (+0.96%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on CAPLIPOINT. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Caplin Point Laboratories Ltd.
Caplin Point Laboratories Limited is a leading Indian pharmaceutical company that engages in the development, production, marketing, and export of generic formulations and branded products. The company offers a diverse portfolio of products, including tablets, capsules, injections, and ophthalmic solutions, catering to various therapeutic areas. With a strong presence in the Indian market, Caplin Point Laboratories has established itself as a reliable player in the domestic pharmaceutical industry. The company's recent receipt of USFDA final approval for Calcium Gluconate Injection USP is a significant development, indicating its ability to meet international quality standards. Caplin Point Laboratories has reported revenue of ₹2092 Cr and net income of ₹614 Cr, with an analyst recommendat
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹1,694 Cr +15.50% | ₹1,937 Cr +14.30% | ₹2,187 Cr |
| EBITDA Margin | 32.53% | 33.40% | 0.00% |
| Net Profit | ₹461.00 Cr +22.30% | ₹541.00 Cr +17.40% | ₹650.00 Cr |
| EPS | ₹60.19 | ₹70.56 | ₹84.36 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Caplin Point Laboratories Limited Revenue Breakdown – NSE:CAPLIPOINT
Enterprise value to revenue forward of Caplin Point Laboratories Limited – NSE:CAPLIPOINT
🔒
+ 3 more stories about Caplin Point Laboratories Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹600 Cr, PAT ₹173 Cr, EPS ₹22.38. Growth context: revenue QoQ +10.5%, PAT QoQ +4.2%. Street verdict: beat, revenue surprise +12.8%, PAT surprise +11.3%.
Recent corporate activity highlights product launches, approvals, and therapy-mix improvement as the primary near-term g...
FY25 (last completed FY): revenue ₹1, 937 Cr, PAT ₹541 Cr, EBITDA margin 33.4%, EPS ₹70.56. Year-on-year: revenue YoY +1...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for CAPLIPOINT
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track CAPLIPOINT alongside your other holdings
Unlock full CAPLIPOINT research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Caplin Point Laboratories Ltd.?
NiveshIQ detects active intelligence signals for Caplin Point Laboratories Ltd. (CAPLIPOINT) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Caplin Point Laboratories Ltd.?
Caplin Point Laboratories Ltd. operates in the Healthcare sector with a market capitalisation of ₹1,410,777.1L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.